Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma

Leukemia

Volumn 11, Issue 10, 1997, Pages 1742-1752

  Van Belzen, N ^a,b,c   Hupkes, P E ^a,b   Doekharan, D ^a   Hoogeveen Westerveld, M ^a,b   Dorssers, L C J ^c   Van't Veer, M B ^a,b  

^a Department Hematology ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Immunoglobulin heavy chain (IgH); Minimal residual disease; Non Hodgkin's lymphoma

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GRADING; CLINICAL ARTICLE; GENE REARRANGEMENT; HUMAN; IMMUNOGLOBULIN GENE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0030723676     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400797     Document Type: Article

References (12)

1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002-1006.
2. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491.
3. Eisenstein BI. The polymerase chain reaction. A new method of using molecular genetics for medical diagnosis. New Engl J Med 1990; 322: 178-183.
4. Van Dongen JJM, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6: 47-59.
5. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
6. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302: 575-581.
7. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane SS, Lange B, Tsujimoto Y, Caton AJ, Rovera G. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989; 86: 5123-5127.
8. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. New Engl J Med 1990; 323: 448-455.
9. Jonsson OG, Kitchens RL, Scott FC, Smith RG. Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood 1990; 76: 2072-2079.
10. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991; 78: 3021-3029.
11. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martiat P. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993; 82: 1618-1625.
12. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukemia. Br J Haematol 1993; 83: 412-418.